I-15 Peiming Ma Organization of Target-Mediated Disposition (TMD) Models including Michaelis-Menten (MM), rapid-binding (RB), and quasi-steady-state (Qss) models Wednesday 10:15-11:45 |
I-20 Eleonora Marostica Second order Markov modelling of HAMD responses in depression trials Wednesday 10:15-11:45 |
I-26 Sven Mensing Evaluation of the long-term decline of platelets following Navitoclax (ABT-263) administration in Cancer Patients with a semi-physiological pharmacodynamic model Wednesday 10:15-11:45 |
I-33 Michael Neely Non-Parametric Bayesian Fitting: A Novel Approach to Population Pharmacokinetic Modeling Wednesday 10:15-11:45 |
I-41 Kayode Ogungbenro A semi-mechanistic gastric emptying model for double peaks in pharmacokinetics using LDOPA data Wednesday 10:15-11:45 |
I-55 Arnaud Quelin How Anti-cancer Targeted Therapies Used in Combination Interact? Analysis with a Semi-mechanistic Model of Minimal Signalling Networks Wednesday 10:15-11:45 |
I-60 Nikita Rodichenko Multimodal Physiologically-Based Modelling and Analysis of Kinetics of Drug-Delivery with Modular Nanotransporters (MNT) Wednesday 10:15-11:45 |
I-67 Alberto Russu A new, second-order indirect model of depression time course Wednesday 10:15-11:45 |
II-03 Mark Sale Identification of optimal NONMEM models using a multi-objective genetic algorithm. Wednesday 15:10-16:40 |
II-11 Eric Sherer Three case studies of pharmacokinetic model building using a multi-objective genetic algorithm Wednesday 15:10-16:40 |
II-22 Alexander Staab A Model-based Meta-analysis Comparison of the Effects of Linagliptin and Sitagliptin on HbA1c Levels in Patients with Type 2 Diabetes Mellitus Wednesday 15:10-16:40 |
II-45 Eline van Maanen A step-wise analysis of multiple biomarkers drives the development of a Semi-Mechanistic Comprehensive Model. Application to modulation of Amyloid-β. Wednesday 15:10-16:40 |
II-66 Kirill Zhudenkov Application of the SBTOOLBOX2 in drug discovery and development Wednesday 15:10-16:40 |
III-22 Michael Block Physiological modeling of inter-individual variability: Combining PBPK modeling and Markov-Chain-Monte-Carlo approaches Thursday 10:05-11:35 |
III-27 Marion Bouillon-Pichault Modeling of pain scores from a flexible titration study using an ordered categorical approaches Thursday 10:05-11:35 |
III-28 Frances Brightman Predicting in vivo drug response and synergistic combinations from three-dimensional tumour cell cultures Thursday 10:05-11:35 |
III-42 Karina Blei Development and evaluation of dynamical whole body Physiologically-based Models of the Circulation and the Renin-Angiotensin-Aldosterone system Thursday 10:05-11:35 |
III-47 Zeinab Daher Abdi Joint model for longitudinal exposure to mycophenolic acid and rejection survival data in the first year after renal transplantation Thursday 10:05-11:35 |
III-51 Giuseppe De Nicolao PCA-based modelling in antidepressant trials: a pre-mechanistic approach Thursday 10:05-11:35 |
III-52 Ivan Demin Posterior predictive check to assess similarity of systemic exposure profiles of an inhaled drug product pre- and post- manufacturing modification. Thursday 10:05-11:35 |
III-58 Pinky Dua A Systems Pharmacology model of the nerve growth factor (NGF) pathway to aid drug discovery and development Thursday 10:05-11:35 |
III-59 Vivek Dua Multi-objective Optimal Control of Non-Viral Gene Delivery Thursday 10:05-11:35 |
IV-19 Linus Görlitz Physiological modeling of interindividual variability: PBPK-NLME vs. compartimental modeling Thursday 15:00-16:30 |
IV-24 Joachim Grevel Response type modelling and clinical trial simulation. Thursday 15:00-16:30 |
IV-45 Alvaro Janda Optimization of pharmacokinetics and pharmacodynamics profiles by optimal control methods. Application to a triptorelin-testosterone PD model. Thursday 15:00-16:30 |